• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Metsera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    5/12/25 7:30:14 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email
    8-K
    false 0002040807 0002040807 2025-05-12 2025-05-12
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): May 12, 2025

     

     

    METSERA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-42489   92-0931552

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    3 World Trade Center  
    175 Greenwich Street  
    New York, New York   10007
    (Address of principal executive offices)   (Zip Code)

    (212) 784-6595

    (Registrant’s telephone number, include area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbols

     

    Name of each exchange

    on which registered

    Common Stock, $0.00001 par value per share   MTSR   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02.

    Results of Operations and Financial Condition.

    On May 12, 2025, Metsera, Inc. announced financial results for the three months ended March 31, 2025 as well as a business update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

       Description
    99.1*    Press Release, dated May 12, 2025.
    104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

     

    *

    Furnished herewith.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        METSERA, INC.
    Date: May 12, 2025     By:  

    /s/ Matthew Lang

          Matthew Lang
          Chief Legal Officer and Secretary
    Get the next $MTSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Metsera with a new price target

      Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00

      2/25/25 7:57:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Metsera with a new price target

      BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00

      2/25/25 7:56:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Metsera

      Evercore ISI initiated coverage of Metsera with a rating of Outperform

      2/25/25 7:56:13 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

      MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead expected in late 2025 $588 million cash and cash equivalents support runway into 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical compa

      5/12/25 7:00:11 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera to Present at Bank of America 2025 Global Healthcare Conference

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines

      5/8/25 4:01:51 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

      MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o, with MET-224o data expected in late 2025 Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medici

      3/26/25 7:00:37 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pinto Joshua

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:42:42 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Chairman Meanwell Clive

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:40:27 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Burow Kristina

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:39:32 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:15:35 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:04:05 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:01:33 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

      SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

      5/12/25 10:36:17 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Metsera Inc.

      10-Q - Metsera, Inc. (0002040807) (Filer)

      5/12/25 7:30:23 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Metsera, Inc. (0002040807) (Filer)

      5/12/25 7:30:14 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care